Synthesis and Preliminary Evaluation of the 211 At-Labeled PARP Inhibitor [ 211 At]Talazoparib as a Targeted Alpha-Particle Emitting Therapeutic
Molecular Pharmaceutics · 06.07.2026 · 23 (7) · 3904-3915
DOI: 10.1021/acs.molpharmaceut.6c00367 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 08.06.2026. Verfasst von Yongxiang Zheng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Duke University Medical Center, Durham, North Carolina 27710, United States. Hauptthemen laut MEDLINE: Phthalazines, Poly(ADP-ribose) Polymerase Inhibitors, Alpha Particles, Astatine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Duke University.
Abstract (Originalsprache)
Poly(ADP-ribose) polymerase-1 (PARP1) has become a crucial target in cancer therapy. In recent years, derivatives of olaparib and rucaparib have been radiolabeled for noninvasive imaging of PARP1 expression and targeted radionuclide therapy of PARP-expressing tumors. Motivated by the superior potency of talazoparib, we developed a novel radiolabeling approach for [211At]talazoparib and report its in vitro and in vivo evaluation. The tin precursors and iodo standards were synthesized, separated on a chiral column, and [211At]talazoparib and its inactive. [211At]LT-674 enantiomer were synthesized in a single step from their respective tin precursor. Radiochemical yield (RCY) and radiochemical purity RCP were determined using RP-HPLC. Cell uptake and internalization were performed on PSMA-positive PC-3 PIP prostate carcinoma cells and U87MG glioma cells and in vitro cytotoxicity (MTT) was evaluated on PC-3 PIP cells. Biodistribution studies were performed in athymic mice with subcutaneous PC-3 PIP xenografts and the therapeutic efficacy of [211At]talazoparib was evaluated in the same animal model. The syntheses of tin precursors and iodo standards was developed and optimized. A one-step and scalable radiolabeling method was developed for the synthesis of [211At]talazoparib with 70 ± 7% (n = 10) RCY in 1 h and >95% RCP. The maximum activity of [211At]talazoparib produced was 370 MBq. High cell uptake and internalization were observed for [211At]talazoparib but not [211At]LT-674 with PC-3 PIP cells, and [211At]talazoparib was cytotoxic to PC3 PIP cells in vitro. High tumor uptake and prolonged retention, and rapid clearance from normal tissues were seen for [211At]talazoparib after intratumoral injection. Tumor growth inhibition and survival benefit were observed with a single dose of intratumorally injected [211At]talazoparib. Methods for the chiral separation of precursor permitted radiolabeling of [211At]talazoparib without the need for separation from its inactive 211At-labeled enantiomer after radiolabeling, and scaled-up production was optimized. [211At]talazoparib exhibited promising potential as a targeted radiotherapeutic, particularly for settings where locoregional administration is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Duke University Medical Center, Durham, North Carolina 27710, United States.
ORCID-Profile: Ganesan Vaidyanathan, Michael R Zalutsky
Förderung
- Duke University
Zitieren
APA
Zheng, Y., Kong, D., Huynh, T. T., Zhao, X., Liu, Y., Banks, R. L., Vaidyanathan, G., Feng, Y., & Zalutsky, M. R. (2026). Synthesis and Preliminary Evaluation of the 211 At-Labeled PARP Inhibitor [ 211 At]Talazoparib as a Targeted Alpha-Particle Emitting Therapeutic. Molecular Pharmaceutics, 23(7), 3904-3915. https://doi.org/10.1021/acs.molpharmaceut.6c00367
Vancouver
Zheng Y, Kong D, Huynh TT, Zhao X, Liu Y, Banks RL, et al. Synthesis and Preliminary Evaluation of the 211 At-Labeled PARP Inhibitor [ 211 At]Talazoparib as a Targeted Alpha-Particle Emitting Therapeutic. Molecular Pharmaceutics. 2026;23(7):3904-3915. doi:10.1021/acs.molpharmaceut.6c00367
BibTeX
@article{Zheng2026,
author = {Zheng, Yongxiang and Kong, Deyu and Huynh, Truc T and Zhao, Xiaoguang and Liu, Yang and Banks, Rebecca L and Vaidyanathan, Ganesan and Feng, Yutian and Zalutsky, Michael R},
title = {Synthesis and Preliminary Evaluation of the 211 At-Labeled PARP Inhibitor [ 211 At]Talazoparib as a Targeted Alpha-Particle Emitting Therapeutic},
journal = {Molecular Pharmaceutics},
year = {2026},
volume = {23},
number = {7},
pages = {3904--3915},
doi = {10.1021/acs.molpharmaceut.6c00367}
}
EUVIMED